THE USE OF LONG-ACTING ?2-AGONISTS AS MONOTHERAPY IN CHILDREN AND ADULTS

Main Article Content

Pat G Camp
Tingting Zhang
M Anne Smith
Bruce C Carleton

Keywords

Adrenergic beta-2 receptor agonists, asthma, drug utilization, pediatrics, pulmonary disease, chronic obstructive

Abstract

Background
In asthma, it is recommended that long-acting ?2-agonists (LABAs) not be used as monotherapy, but, be used with inhaled corticosteroids (ICS) to minimize the risk of serious adverse events.



Objective
To test the hypothesis that if clinical recommendations were followed, LABA monotherapy would not occur in children and would only occur in COPD, where it is not contraindicated.



Methods
We analyzed LABA and ICS dispensing for British Columbians with respiratory conditions in 2004. LABA use was classified as “LABA Monotherapy”, “LABA with Concurrent ICS”, or “Mixed” (LABA use, occasional ICS use). Using physician and hospital billing records, children < 18 years were classified as having “asthma” or “other respiratory condition”. Adults were classified as having “asthma”, “COPD”, “asthma and COPD”, or “other respiratory condition”. We calculated the prevalence of LABA monotherapy, and the association between LABA monotherapy and diagnosis, age, gender, and location of residence.



Results
LABA monotherapy occurred in 3.4% (n=140) of pediatric and 3.9% (n=1837) of adult LABA users and in 3.4% of children with asthma and 3.0% of adults with asthma. In children, LABA monotherapy was associated with female gender (odds ratio (OR) 1.62; 95% confidence interval (CI) 1.14, 2.82; p<0.0065) and adolescence (age 12-18 years; 2.30; CI 1.53,3.46; p<0.0001). In adults, LABA monotherapy was associated with a COPD diagnosis, and being greater than 60 years old (p<0.0001).



Conclusion
LABA monotherapy occurs in children and adults. LABA monotherapy in children, especially in girls and adolescents, could expose them to serious adverse events and requires further study.

Abstract 152 | PDF Downloads 77

References

1. Boulet LP, Bai TR, Becker A. What is new since the last (1999) Canadian Asthma Consensus Guidelines? Can Respir J 2001;8 (Suppl A):5A-27A.
2. Becker A, Berube D, Chad Z, et al. Canadian Pediatric Asthma Consensus guidelines, 2003 (updated to December 2004): Introduction. CMAJ 2005;173(6 Suppl):S12-4.
3. Lougheed MD, Lemiere C, Dell SD, et al. Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults. Can Respir J 2010;17(1):15-24.
4. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31(1):143-78.
5. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
6. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals Intern Med 2006;144 (12):904-12.
7. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16(5):802-7.
8. Lai CK, De Guia TS, Kim YY, et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol 2003;111(2):263-8.
9. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults: the global Asthma Insights and Reality surveys. J Allergy Clin Immunol 2004;114(1):40-7.
10. O'Donnell DE, Hernandez P, Aaron S, et al. Canadian Thoracic Society COPD guidelines: Summary of highlights for family doctors. Can Respir J 2003;10:183-5.
11. O'Donnell DE, Hernandez P, Aaron S, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007;14 (Supp.B):5B-32B.
12. Lemiere C, Bai T, Balter M, et al. Adult Asthma Consensus Guidelines update 2003. Can Respir J 2004;11(Suppl A):9A-18A.
13. British Columbia Ministry of Health Services, PharmaNet Database. 2004.
14. British Columbia Ministry of Health Services, Medical Services Billing Database. 2004.
15. British Columbia Ministry of Health Services, Hospital Discharge Abstracts Database. 2004.
16. Curkendall SM, de Luise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16(1):63-70.
17. Hosmer DW, Lemeshow S. Applied Logistic Regression Second Ed. 2000, New York: Wiley.
18. Yawn BP, Wollan PC, Bertram SL, et al. Asthma treatment in a population-based cohort: putting step-up and step-down treatment changes in context. Mayo Clin Proc 2007 Apr;82(4):414-21.
19. Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G. Retrospective claims study of fluticason propionate / salmeterol fixed-dose combination use in initial asthma controller therapy in children despite guideline recommendations. Clin Ther 2009;31:1056-63.
20. Thomas M, Murray-Thomas T, Fan T, Williams T, Taylor S. Prescribing patterns of asthma controller therapy for children in UK primary care: a cross-sectional observational study. BMC Pulm Med 2010;14(10):29.
21. Wasilevich EA, Clark SJ, Cohn LM, Dombkowski KJ. Long-acting beta-agonist monotherapy among children and adults with asthma. Am J Manag Care 2011;17(4):e91-95.
22. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176(2):162-6

Most read articles by the same author(s)